Skip to content

Synovial Sarcoma Registry / Biospecimen Repository

Synovial Sarcoma Registry and Biospecimen Repository

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05910307
Enrollment
1000
Registered
2023-06-18
Start date
2023-06-12
Completion date
2033-06-01
Last updated
2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Synovial Sarcoma

Keywords

registry, biorepository, sarcoma, oncology, cancer, rare tumor

Brief summary

The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing. Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.

Detailed description

This study will enroll patients with a diagnosis of Synovial Sarcoma. Following consent, demographic, clinical, treatment and outcome data will be collected from an interview and/or online survey. This will include a request for contact information for the subject's treating hospitals/physicians and a release of records request to obtain medical records. At approximately 6-12 month intervals for up to 10 years after initial diagnosis and/or relapse, subjects and/or their treating hospitals may be contacted to provide updates on treatment and outcomes. Tumor samples may be collected from residual material obtained during clinically indicated procedures occurring before or after consent to this study. No additional material will be collected or procedures performed solely for the purpose of this study. Blood may be collected at the participant's local institution at the time of a clinically indicated blood draw and/or saliva or a buccal swab may be collected as a germline sample and for analysis of circulating free DNA (cfDNA) and/or circulating tumor cells (CTCs). Genetic testing may be performed on tumor and germline samples submitted by subjects. Results will only be returned if deemed clinically significant.

Interventions

None listed

Sponsors

Children's Hospital of Philadelphia
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Males or females of any age 2. Reported diagnosis of synovial sarcoma 3. Informed consent from subject (aged ≥18 years) or parent/guardian

Exclusion criteria

1. Individuals with sarcomas that do not fit the definition of those considered for this registry 2. Individuals who are unwilling to participate 3. Individuals who are unwilling or unable to provide written consent

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with synovial sarcomaUp to 10 yearsNumber of patients with synovial sarcoma

Countries

United States

Contacts

CONTACTLauren Gutstein
gutsteinl1@chop.edu267-425-2029
CONTACTJames Robinson
robinsonj9@chop.edu215-590-2053
PRINCIPAL_INVESTIGATORTheodore Laetsch, MD

Children's Hospital of Philadelphia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 10, 2026